Targeting the mitotic checkpoint to kill tumor cells.

Area of Science:

• Cell Biology
• Cancer Research
• Genetics

Background:

• Aneuploidy, an abnormal chromosome number, is a common characteristic of cancer cells.
• This arises from chromosome missegregation during mitosis, a frequent event in tumor cell divisions.
• Chromosome instability (CIN) is prevalent in human tumors, leading to variegated aneuploidy.

Purpose of the Study:

• To investigate if aneuploidy can be exploited as an anti-cancer therapeutic target.
• To test the hypothesis that inhibiting the mitotic checkpoint could selectively harm tumor cells.

Main Methods:

• Inactivation of the mitotic checkpoint using RNA interference (RNAi)-mediated depletion of Mps1.
• Assessing the impact of mitotic checkpoint inactivation on chromosome segregation fidelity.
• Quantifying cell death in tumor cells following checkpoint inhibition.

Main Results:

• Depletion of Mps1 led to a significant increase in chromosome missegregation errors during mitosis.
• This increase in segregation errors was directly correlated with enhanced cell death in tumor cells.
• Inhibition of the mitotic checkpoint effectively induced cell death in cancer cells.

Conclusions:

• The study supports the hypothesis that targeting the mitotic checkpoint is a viable anti-cancer strategy.
• Exploiting chromosome missegregation through mitotic checkpoint inhibition shows promise for cancer therapy.
• Mitotic checkpoint inhibition represents a potential therapeutic approach for treating aneuploid tumors.